F. Hoffmann-La Roche AG Revenue in 2024

F. Hoffmann-La Roche AG reported $66.5B in revenue for fiscal year 2024.

CHF 59.4 billion in FY2024 revenue represents one of the largest pharmaceutical revenue bases in the world, generated by a company that operates with pharmaceutical gross margins consistently above 80 percent. The CHF 15.8 billion annual R&D investment — roughly 26 percent of revenue — is the financial commitment required to maintain a pipeline that can continuously replace drugs losing exclusivity to biosimilar competition. The diagnostics segment, approximately 25 percent of revenue, operates at margins below the pharmaceutical segment but provides a strategic value that financial statements do not capture directly: the diagnostic data that informs pharmaceutical R&D and identifies patient populations most likely to respond to specific drugs. A pharmaceutical trial that enrolls the right patients because of companion diagnostic stratification has materially higher success rates, which translates directly into reduced development cost and time for the pharmaceutical segment. The $250 billion market capitalization reflects investor confidence in the pipeline's ability to sustain revenue growth past the biosimilar competition period for legacy oncology biologics. Herceptin, Avastin, and MabThera — the drugs that drove Roche's oncology dominance for years — now face biosimilar competition in major markets, creating revenue pressure that the new generation of drugs must offset. The dual-class share structure at Roche, controlled by the Hoffmann and Oeri families, provides the long-term governance stability that supports the multi-decade R&D investment cycle. A company that spends CHF 15.8 billion annually on research needs a capital structure that insulates management from short-term earnings pressure; the family-controlled structure provides that insulation while maintaining public market liquidity through the non-voting bearer shares.